Thermo Fisher Scientific vs Hitachi: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Thermo Fisher Scientific Inc (TMO)

Q3 202623 Jul – 15 Sep 2026

▲4

Thermo Fisher Q2 Beat, Raised Guidance, and New Product Launches Drive Stock Up 8.7%

Q2 Earnings Beat and Raised Guidance Thermo Fisher reported Q2 revenue up 10% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year guidance to $47.4–48.1 billion, boosting investor confidence.
This is the primary new financial event that directly drove the stock price higher.
Analyst Target Hikes and Stock Surge Following the strong earnings, analysts at Jefferies and RBC raised their price targets to $630 and $580, respectively. Shares jumped 8.7% to $572.32 as a result.
This shows the direct market reaction and validation from analysts, which is new information.
New Product and Partnership Developments Thermo Fisher received FDA 510(k) clearance for its EXENT myeloma test, partnered with ImmuPharma for manufacturing, and took a minority stake in Mayo Clinic's Precure venture, expanding its clinical and manufacturing reach.
These are new strategic moves that support future growth and were not reported in the previous period.
Broad Demand Recovery and Competitive Gains Thermo Fisher saw a broad demand recovery, outpacing competitor Danaher, with its Analytical Instruments unit returning to growth. This indicates strengthening market position and durable recurring revenue.
This highlights the underlying business momentum that drove the stock and is new to this period.

August 202626 Jul – 15 Sep 2026

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.
This is the core new event that reset expectations for the company's earnings power.
Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.
It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.
FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.
A new regulatory approval expands the product portfolio and future revenue.
Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.
A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

Latest26 Jul – 15 Sep 2026

▲4

Thermo Fisher's Life-Sciences Recovery Gains Steam as New Deals and Clearances Build

Q2 beat and raised guidance Thermo Fisher reported 10% revenue growth to $11.99 billion and 13% EPS growth, then raised full-year revenue guidance to $47.4–$48.1 billion. Analysts lifted price targets, with RBC going to $580 from $490. Strong results and a brighter outlook push the stock up because investors pay more for faster, more reliable profit growth.
This is the core new event that reset expectations for the company's earnings power.
Broad demand recovery, outpacing Danaher Organic revenue rose 5% and management pointed to improving customer activity across pharma and biotech, while the Analytical Instruments unit returned to growth after two weak years. Rival Danaher cut its growth outlook, so Thermo Fisher looks like a share gainer. A recovering end-market lifts the stock because it suggests the slump in life-sciences spending is ending.
It shows the demand recovery is real and Thermo Fisher is winning relative to a key competitor.
FDA clearance for EXENT myeloma test Thermo Fisher won FDA 510(k) clearance for its EXENT automated mass-spectrometry platform for multiple myeloma, strengthening its specialty cancer diagnostics. New approved products open fresh revenue streams and support higher-margin recurring sales, which investors view as a durable positive for the stock.
A new regulatory approval expands the product portfolio and future revenue.
Mayo Clinic Precure venture Thermo Fisher became a minority owner in Precure, LLC, a Mayo Clinic-led venture building molecular data from one million biospecimens, contributing its Olink proteomics platform, Orbitrap mass spectrometers, kits and reagents. The deal creates a large new outlet for its products and validates its technology, supporting the stock.
A new partnership provides a visible long-term demand channel for Thermo Fisher's instruments and reagents.

July 202623 Jul – 24 Jul 2026

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.
This is the core new event that answers why the stock is moving now.
Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.
This shows the immediate market reaction and analyst validation, which are key to the price move.
New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.
This is a new contract that adds to the growth story and supports the positive outlook.

23 Jul – 24 Jul 2026

▲3

Thermo Fisher Q2 Beat and Raised Guidance Drive Stock Higher

Q2 earnings beat and raised full-year guidance Thermo Fisher reported Q2 revenue up 10.5% to $11.99 billion and adjusted EPS of $6.03, beating expectations. Management raised full-year revenue and EPS guidance, signaling confidence in continued momentum. This directly boosts the stock as it shows the company is growing faster than expected and expects that to continue.
This is the core new event that answers why the stock is moving now.
Stock jumps 8.7% on earnings and analyst upgrades Shares climbed 8.7% to $572.32 after the earnings report, and three analysts raised their price targets, with Jefferies going to $630. Upgrades from Wall Street often pull in more buyers, pushing the price higher in the short term and reflecting improved sentiment.
This shows the immediate market reaction and analyst validation, which are key to the price move.
New manufacturing partnership with ImmuPharma Thermo Fisher was selected by ImmuPharma to make its diabetes treatment Kapiglucagon. This adds a new project to Thermo Fisher's drug manufacturing services, bringing in potential future revenue and showing that its services are in demand. It supports the stock by expanding its business.
This is a new contract that adds to the growth story and supports the positive outlook.

Q2 202622 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

June 202622 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

22 Jun – 7 Jul 2026

▲3▼1

Thermo Fisher expands AI, manufacturing, and clinical reach; Q1 stock drop lingers

AI and manufacturing expansions at BIO 2026 Thermo Fisher unveiled AI partnerships with NVIDIA and OpenAI, new manufacturing capacity, and clinical trial expansions. These moves position the company for future growth in high-demand areas, supporting the stock price by showing innovation and capacity to capture more business.
This is a major new strategic push that could drive future revenue and investor optimism.
Drug discovery market growth A new report projects the drug discovery technologies market to grow 11% annually to $51.5 billion by 2030, with AI-based discovery growing fastest. As a key player, Thermo Fisher is well-placed to benefit from this rising demand, which supports its stock price.
It highlights a favorable industry trend that directly benefits TMO's core business.
Q1 revenue beat but stock fell 5.2% Thermo Fisher reported Q1 revenue up 6.2% and beat estimates, but the stock dropped 5.2% after the report. This suggests investors had even higher expectations or concerns about future growth, creating a negative overhang on the shares.
It explains a recent negative price reaction that may still affect investor sentiment.
New CDMO and clinical collaborations Thermo Fisher became the exclusive CDMO for AustinPx's KinetiSol technology and partnered with Arcturus for Phase 3 manufacturing of a cystic fibrosis therapy. These deals expand its service offerings and add potential revenue streams, supporting the stock.
These are concrete new business wins that can drive revenue and show competitive strength.

Hitachi, Ltd. (6501.JP)

Q3 202617 Jun – 16 Sep 2026

▲3▼1

Hitachi lifted profit outlook on AI data-center power demand

AI data-center power demand boosts profit forecast Hitachi raised its full-year net profit forecast 12.2% to ¥900bn, driven by strong demand for power equipment used in AI data centers. Q1 adjusted operating profit jumped 39.5%, with Digital Systems & Services leading at ¥450bn and Energy profit up 65%.
This is the main new positive force behind the stock this quarter.
Expanded AI partnerships and new services Hitachi expanded its partnership with OpenAI, joined Nvidia's physical AI coalition, launched a crypto anti-money-laundering service, and saw growing demand for rail batteries. These moves position Hitachi in fast-growing AI and digital markets.
New strategic partnerships and services that could drive future growth.
Hitachi Energy invests in US transformer plant Hitachi Energy committed $528m to a Mississippi transformer plant and signed an MoU with Mission Critical Group for data-center power equipment. This expands US capacity to meet AI-driven electricity demand.
Significant capital investment to capture growing US power infrastructure demand.
Risks: AI reliance, execution, and cash outlay Q1 net profit dipped slightly. Risks include heavy reliance on AI-driven demand, execution challenges in new partnerships and markets, and the Mississippi plant's cash outlay with payoff only from 2029.
These are real counterweights that could pressure the stock if they materialize.

August 202613 Aug – 16 Sep 2026

▲4

Hitachi rides AI power and data-center demand with record profits and US expansion

Nvidia physical AI coalition Hitachi joined Nvidia's physical AI coalition, building robots and industrial AI on Nvidia's platforms. This ties Hitachi to Japan's huge government-backed AI robotics push, a long-term source of orders for its digital and industrial businesses, supporting the shares.
New partnership signals durable AI-driven demand for Hitachi.
Digital unit leads profit Full-year results show Hitachi's Digital Systems & Services unit earned 450 billion yen, the most of any segment, with a 16.3% margin, while Energy profit jumped 65%. Strong, higher-margin earnings underpin the stock and justify its recovery toward the 5,400 yen range.
Earnings power is the core fundamental driver of the share price.
US transformer factory Hitachi Energy will spend $528 million (about 82 billion yen) on a Mississippi transformer plant, part of a $1.5 billion US expansion, to meet AI-driven electricity demand. It adds long-term capacity and revenue, though the cash outlay and 2029 start mean payoff is years away.
Major capex shows Hitachi positioning for AI power demand.
Data-center partnership Hitachi signed an MoU with Mission Critical Group to jointly build and sell data-center power and modular equipment, combining Hitachi Energy and digital tech with MCG's 18 US factories. It widens Hitachi's reach into a market growing about 20% a year, supporting future orders.
New partnership expands Hitachi's data-center addressable market.

Latest13 Aug – 16 Sep 2026

▲4

Hitachi rides AI power and data-center demand with record profits and US expansion

Nvidia physical AI coalition Hitachi joined Nvidia's physical AI coalition, building robots and industrial AI on Nvidia's platforms. This ties Hitachi to Japan's huge government-backed AI robotics push, a long-term source of orders for its digital and industrial businesses, supporting the shares.
New partnership signals durable AI-driven demand for Hitachi.
Digital unit leads profit Full-year results show Hitachi's Digital Systems & Services unit earned 450 billion yen, the most of any segment, with a 16.3% margin, while Energy profit jumped 65%. Strong, higher-margin earnings underpin the stock and justify its recovery toward the 5,400 yen range.
Earnings power is the core fundamental driver of the share price.
US transformer factory Hitachi Energy will spend $528 million (about 82 billion yen) on a Mississippi transformer plant, part of a $1.5 billion US expansion, to meet AI-driven electricity demand. It adds long-term capacity and revenue, though the cash outlay and 2029 start mean payoff is years away.
Major capex shows Hitachi positioning for AI power demand.
Data-center partnership Hitachi signed an MoU with Mission Critical Group to jointly build and sell data-center power and modular equipment, combining Hitachi Energy and digital tech with MCG's 18 US factories. It widens Hitachi's reach into a market growing about 20% a year, supporting future orders.
New partnership expands Hitachi's data-center addressable market.

July 202617 Jun – 30 Jul 2026

▲3▼1

Hitachi lifts profit outlook on AI demand, expands tech partnerships

AI partnerships and recognition Hitachi expanded its OpenAI partnership for banking and cybersecurity, earned WEF recognition for its Oklahoma plant, and joined Nvidia's physical AI coalition, strengthening its AI credentials.
These moves highlight Hitachi's growing AI ecosystem and potential for future revenue.
Raised profit forecast on AI data-center power demand Hitachi raised its full-year net profit forecast by 12.2% to ¥900bn, driven by AI data-center power demand, and reported Q1 adjusted operating profit up 39.5%.
This directly reflects improved financial performance and outlook, a key driver for the stock.
New services and market expansion Hitachi announced a new crypto AML service and saw expanded rail battery demand, indicating diversification into new areas and additional revenue streams.
These initiatives show Hitachi's efforts to broaden its business beyond core segments.
Q1 net profit dip and execution risks Despite overall strength, Q1 net profit declined slightly, and reliance on AI-driven demand plus execution challenges in new partnerships and markets temper the positive outlook.
This provides a balanced view by highlighting potential headwinds that could affect future performance.

20 Jul – 30 Jul 2026

▲4

Hitachi lifts profit outlook on AI data-center power demand

Hitachi raises full-year profit forecast on AI data-center power demand Hitachi lifted its full-year net profit forecast to 900 billion yen, up 12.2%, and adjusted operating profit to 1.408 trillion yen. The upgrade is driven by strong sales of power transmission equipment used in AI data centers, showing its energy business is a real growth engine.
This is the main new event that directly answers why the stock is moving now.
Q1 profit dips slightly but core operating profit jumps 39.5% First-quarter net profit slipped 1.4% to 189.45 billion yen, but adjusted operating profit surged 39.5% to 294.2 billion yen and revenue rose to 2.71 trillion yen. The profit dip is minor; the strong underlying operating performance supports the upbeat outlook.
It shows the earnings quality behind the raised forecast, which investors care about.
New anti-money laundering service for crypto assets Hitachi will launch an AML monitoring service in October for crypto, stablecoins, and NFTs, after a proof-of-concept with 17 financial and crypto firms. This opens a new revenue stream in digital-asset compliance, a fast-growing area, and shows Hitachi's ability to turn regulation into business.
It is a new product launch that adds a future growth driver beyond the current earnings story.
Rail battery expansion signals strong train orders Turntide is expanding battery production because of demand from Hitachi Rail, supporting hybrid trains built in the UK. This points to a healthy order book in Hitachi's rail business, adding to confidence in its industrial segment.
It is a fresh demand signal for Hitachi's rail unit, which is part of the overall growth picture.

17 Jun – 16 Jul 2026

▲4

Hitachi deepens AI ties with OpenAI and Nvidia, turning AI into real products

OpenAI partnership expands into legacy systems and cybersecurity Hitachi is widening its OpenAI work: joint engineer teams will use OpenAI's Codex AI to read and modernize old bank computer systems, and Hitachi gets OpenAI cyber models to defend against attacks. This makes Hitachi's AI services more valuable and opens a new market, supporting the share price.
A concrete new partnership that expands Hitachi's AI business and revenue opportunity.
Oklahoma factory wins WEF Global Lighthouse recognition Hitachi Vantara's Oklahoma storage plant was named a World Economic Forum Lighthouse factory after AI cut order-to-shipment time 77% and inventory 50%. Hitachi will fold these proven AI methods into its HMAX product suite, showing customers real results and strengthening its AI-selling story.
New proof point that Hitachi's own AI works, boosting credibility and future sales.
Hitachi joins Nvidia's physical AI push in Japan At Nvidia's Tokyo event, Hitachi said it will join the Cosmos Coalition for open physical AI models and work with Nvidia to integrate and control whole sites like factories and power plants. This positions Hitachi in the fast-growing robot-and-factory AI market, a positive for future orders.
New Nvidia partnership directly ties Hitachi to the physical AI theme investors are watching.
Intel foundry interest and Hitachi physical AI tie reinforce chip supply Reports say Google and Nvidia may use Intel's chip factories as capacity runs short, and Intel and Hitachi already announced a June collaboration on physical AI and next-generation computing. Stronger Intel foundry prospects support the hardware side of Hitachi's AI and infrastructure plans.
Links Hitachi's earlier Intel tie to a broader chip-supply story that underpins its AI hardware.